MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

107.69
+4.33
+4.19%
After Hours: 107.53 -0.16 -0.15% 16:11 09/19 EDT
OPEN
103.63
PREV CLOSE
103.36
HIGH
109.70
LOW
102.38
VOLUME
248.75K
TURNOVER
--
52 WEEK HIGH
133.96
52 WEEK LOW
53.21
MARKET CAP
5.12B
P/E (TTM)
-23.5280
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASND and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ASND News

  • When Will Ascendis Pharma A/S (NASDAQ:ASND) Run Out Of Money?
  • Simply Wall St..10h ago
  • Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon CNP at International Skeletal Dysplasia Society Meeting
  • GlobeNewswire.09/12 21:20
  • Ascendis Pharma Perhaps Not Best Of 76 Compared Biotechs
  • Seeking Alpha - Article.09/12 12:01
  • Ascendis Pharma (ASND) Presents At 2019 Wells Fargo Healthcare Conference - Slideshow
  • Seeking Alpha - Article.09/05 19:01

More

Industry

Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About ASND

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
More

Webull offers Ascendis Pharma A/S (ASND) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.